Full-Time
Develops and commercializes biopharmaceuticals and vaccines
No salary listed
Expert
Mumbai, Maharashtra, India
Get referrals →
You have ways to get a Takeda referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 4 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline that includes 11 NMEs, with plans for up to 15 product launches by FY2024. Takeda's products are aimed at healthcare providers, hospitals, and patients around the world, and the company collaborates with about 41,000 suppliers to ensure the production and distribution of its medicines. Unlike many competitors, Takeda emphasizes patient-centric values, ensuring that the needs of patients guide its operations. Additionally, Takeda is committed to environmental sustainability, recognizing the connection between environmental health and human health. The company's goal is to provide life-changing treatments while also addressing environmental risks.
Company Size
10,001+
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1781
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Wellness Program
Tuition Reimbursement
A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.
( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.
Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.
ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.
Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.